title: Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination.
abstract: Drug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose- and time-dependent manner. We further investigated the expression profiles of genes involved in drug resistance and metabolism with a Human Cancer Drug Resistance and Metabolism PCR Array (SuperArray). Six of the 84 genes that are known to regulate drug resistance, metabolism, cell cycle, DNA repair and oncogenesis were downregulated >or=3-fold change by the combination treatment. These results may be important in devising mechanism-based and targeted therapeutic strategies for prostate cancer, especially in devising combination therapy for drug resistant prostate cancers.
authors.affiliation: Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Izmir, Turkey.
authors.forename: Ercument
authors.initials: E
authors.lastname: Cengiz
authors.forename: Burcak
authors.initials: B
authors.lastname: Karaca
authors.forename: Yuksel
authors.initials: Y
authors.lastname: Kucukzeybek
authors.forename: Gurbuz
authors.initials: G
authors.lastname: Gorumlu
authors.forename: Mustafa K
authors.initials: MK
authors.lastname: Gul
authors.forename: Cigdem
authors.initials: C
authors.lastname: Erten
authors.forename: Harika
authors.initials: H
authors.lastname: Atmaca
authors.forename: Selim
authors.initials: S
authors.lastname: Uzunoglu
authors.forename: Bulent
authors.initials: B
authors.lastname: Karabulut
authors.forename: Ulus A
authors.initials: UA
authors.lastname: Sanli
authors.forename: Ruchan
authors.initials: R
authors.lastname: Uslu
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D018076:DNA, Complementary / Q000235:genetics; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006072:Gossypol / Q000494:pharmacology*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D018076:DNA, Complementary; D043823:Taxoids; D000077143:Docetaxel; D006072:Gossypol